ACTL6A and ovarian cancer: Notably, drug sensitivity prediction modeling uncovered selective inhibitory effects of HER2 inhibitors (e.g., CP724714) against ACTL6A-high ovarian cancer cells, suggesting that targeting receptor tyrosine kinase signaling may overcome ACTL6A-mediated chemoresistance.